Bausch Health Companies (BHC) Non-Current Deffered Revenue (2009 - 2012)
Bausch Health Companies' (BHC) quarterly Non-Current Deffered Revenue came in at $36.1 million in Q4 2012, down 5.31% year-on-year from $38.2 million in Q1 2012, and down 1.63% quarter-over-quarter from $36.7 million in Q3 2012.
Bausch Health Companies (BHC) Non-Current Deffered Revenue (2009 - 2012) Analysis & Trends
Bausch Health Companies has disclosed Non-Current Deffered Revenue across 4 years of filings, most recently posting $36.1 million for Q4 2012.
- Non-Current Deffered Revenue for Q4 2012 came in at $36.1 million, down 5.31% year-over-year; the trailing twelve-month figure through Dec 2012 was $36.1 million (down 5.31% YoY), and the FY2012 annual result was $36.1 million, down 5.31% from the prior year.
- Non-Current Deffered Revenue came in at $36.1 million for Q4 2012 at Bausch Health Companies, down from $36.7 million in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $69.2 million in Q4 2009 to a low of $34.0 million in Q1 2012.
- The 4-year median for Non-Current Deffered Revenue is $42.0 million (2011), against an average of $45.5 million.
- Across the five-year window, Non-Current Deffered Revenue declined 28.5% in 2011 and slipped 5.31% in 2012, its largest moves.
- Bausch Health Companies' Non-Current Deffered Revenue stood at $69.2 million in 2009, then declined by 27.76% to $50.0 million in 2010, then dropped by 23.73% to $38.2 million in 2011, then dropped by 5.31% to $36.1 million in 2012.
- The last three Non-Current Deffered Revenue figures came in at $36.1 million (Q4 2012), $36.7 million (Q3 2012), and $37.9 million (Q2 2012), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | - |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | - |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | - |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | - |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | - |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | - |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | - |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | - |
| 10 | Bausch Health Companies | 1.93 Bn | 1.59 Bn | 2.48 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2012 | 36.13 Mn |
| Sep 30, 2012 | 36.73 Mn |
| Jun 30, 2012 | 37.90 Mn |
| Mar 31, 2012 | 33.97 Mn |
| Dec 31, 2011 | 38.15 Mn |
| Sep 30, 2011 | 41.41 Mn |
| Jun 30, 2011 | 42.51 Mn |
| Mar 31, 2011 | 45.02 Mn |
| Dec 31, 2010 | 50.02 Mn |
| Sep 30, 2010 | 55.03 Mn |
| Jun 30, 2010 | 59.45 Mn |
| Dec 31, 2009 | 69.25 Mn |